Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation

Shane J. Larue, Rafael Garcia-Cortes, Michael E. Nassif, Justin M. Vader, Shuddhadeb Ray, Ashwin Ravichandran, Ravi Rasalingham, Scott C. Silvestry, Gregory A. Ewald, I-Wen Wang, Joel D. Schilling

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Summary: Introduction: Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. Aims: We sought to evaluate the safety and clinical course of patients treated with bosentan, an endothelin receptor antagonist, after the implementation of a LVAD. Results: Between 10/2008 and 5/2011, 50 consecutive patients with mean PAP >25 mmHg were treated with bosentan after LVAD implantation for a mean duration of 15.7 (±12.4) months. Ten patients discontinued the drug for possible side effects, including three for LFT abnormalities. Comparison of baseline to 6-month follow-up data revealed laboratory evidence for decongestion with a decrease in bilirubin (2.3-0.6, P <0.0001) and an improvement in pulmonary hemodynamics with echocardiographically calculated mean PVR decreasing 1.4 woods units (3.93 ± 1.53 to 2.58 ± 1.05, P <0.0001). Conclusion: In this single-centered retrospective case series, we provide evidence that the tolerability of bosentan in LVAD-supported patients with secondary PH is comparable to prior experience in patients with heart failure.

Original languageEnglish (US)
Pages (from-to)50-55
Number of pages6
JournalCardiovascular Therapeutics
Volume33
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Heart-Assist Devices
Pulmonary Hypertension
Therapeutics
Right Ventricular Dysfunction
Lung
bosentan
Drug-Related Side Effects and Adverse Reactions
Vasodilator Agents
Bilirubin
Heart Failure
Hemodynamics
Safety

Keywords

  • Bosentan
  • Pulmonary vasodilator
  • Secondary pulmonary hypertension
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Larue, S. J., Garcia-Cortes, R., Nassif, M. E., Vader, J. M., Ray, S., Ravichandran, A., ... Schilling, J. D. (2015). Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation. Cardiovascular Therapeutics, 33(2), 50-55. https://doi.org/10.1111/1755-5922.12111

Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation. / Larue, Shane J.; Garcia-Cortes, Rafael; Nassif, Michael E.; Vader, Justin M.; Ray, Shuddhadeb; Ravichandran, Ashwin; Rasalingham, Ravi; Silvestry, Scott C.; Ewald, Gregory A.; Wang, I-Wen; Schilling, Joel D.

In: Cardiovascular Therapeutics, Vol. 33, No. 2, 01.04.2015, p. 50-55.

Research output: Contribution to journalArticle

Larue, SJ, Garcia-Cortes, R, Nassif, ME, Vader, JM, Ray, S, Ravichandran, A, Rasalingham, R, Silvestry, SC, Ewald, GA, Wang, I-W & Schilling, JD 2015, 'Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation', Cardiovascular Therapeutics, vol. 33, no. 2, pp. 50-55. https://doi.org/10.1111/1755-5922.12111
Larue, Shane J. ; Garcia-Cortes, Rafael ; Nassif, Michael E. ; Vader, Justin M. ; Ray, Shuddhadeb ; Ravichandran, Ashwin ; Rasalingham, Ravi ; Silvestry, Scott C. ; Ewald, Gregory A. ; Wang, I-Wen ; Schilling, Joel D. / Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation. In: Cardiovascular Therapeutics. 2015 ; Vol. 33, No. 2. pp. 50-55.
@article{dd62d8e024b24fbab52c09ceb810ca35,
title = "Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation",
abstract = "Summary: Introduction: Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. Aims: We sought to evaluate the safety and clinical course of patients treated with bosentan, an endothelin receptor antagonist, after the implementation of a LVAD. Results: Between 10/2008 and 5/2011, 50 consecutive patients with mean PAP >25 mmHg were treated with bosentan after LVAD implantation for a mean duration of 15.7 (±12.4) months. Ten patients discontinued the drug for possible side effects, including three for LFT abnormalities. Comparison of baseline to 6-month follow-up data revealed laboratory evidence for decongestion with a decrease in bilirubin (2.3-0.6, P <0.0001) and an improvement in pulmonary hemodynamics with echocardiographically calculated mean PVR decreasing 1.4 woods units (3.93 ± 1.53 to 2.58 ± 1.05, P <0.0001). Conclusion: In this single-centered retrospective case series, we provide evidence that the tolerability of bosentan in LVAD-supported patients with secondary PH is comparable to prior experience in patients with heart failure.",
keywords = "Bosentan, Pulmonary vasodilator, Secondary pulmonary hypertension, Ventricular assist device",
author = "Larue, {Shane J.} and Rafael Garcia-Cortes and Nassif, {Michael E.} and Vader, {Justin M.} and Shuddhadeb Ray and Ashwin Ravichandran and Ravi Rasalingham and Silvestry, {Scott C.} and Ewald, {Gregory A.} and I-Wen Wang and Schilling, {Joel D.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/1755-5922.12111",
language = "English (US)",
volume = "33",
pages = "50--55",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation

AU - Larue, Shane J.

AU - Garcia-Cortes, Rafael

AU - Nassif, Michael E.

AU - Vader, Justin M.

AU - Ray, Shuddhadeb

AU - Ravichandran, Ashwin

AU - Rasalingham, Ravi

AU - Silvestry, Scott C.

AU - Ewald, Gregory A.

AU - Wang, I-Wen

AU - Schilling, Joel D.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Summary: Introduction: Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. Aims: We sought to evaluate the safety and clinical course of patients treated with bosentan, an endothelin receptor antagonist, after the implementation of a LVAD. Results: Between 10/2008 and 5/2011, 50 consecutive patients with mean PAP >25 mmHg were treated with bosentan after LVAD implantation for a mean duration of 15.7 (±12.4) months. Ten patients discontinued the drug for possible side effects, including three for LFT abnormalities. Comparison of baseline to 6-month follow-up data revealed laboratory evidence for decongestion with a decrease in bilirubin (2.3-0.6, P <0.0001) and an improvement in pulmonary hemodynamics with echocardiographically calculated mean PVR decreasing 1.4 woods units (3.93 ± 1.53 to 2.58 ± 1.05, P <0.0001). Conclusion: In this single-centered retrospective case series, we provide evidence that the tolerability of bosentan in LVAD-supported patients with secondary PH is comparable to prior experience in patients with heart failure.

AB - Summary: Introduction: Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. Aims: We sought to evaluate the safety and clinical course of patients treated with bosentan, an endothelin receptor antagonist, after the implementation of a LVAD. Results: Between 10/2008 and 5/2011, 50 consecutive patients with mean PAP >25 mmHg were treated with bosentan after LVAD implantation for a mean duration of 15.7 (±12.4) months. Ten patients discontinued the drug for possible side effects, including three for LFT abnormalities. Comparison of baseline to 6-month follow-up data revealed laboratory evidence for decongestion with a decrease in bilirubin (2.3-0.6, P <0.0001) and an improvement in pulmonary hemodynamics with echocardiographically calculated mean PVR decreasing 1.4 woods units (3.93 ± 1.53 to 2.58 ± 1.05, P <0.0001). Conclusion: In this single-centered retrospective case series, we provide evidence that the tolerability of bosentan in LVAD-supported patients with secondary PH is comparable to prior experience in patients with heart failure.

KW - Bosentan

KW - Pulmonary vasodilator

KW - Secondary pulmonary hypertension

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84925358507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925358507&partnerID=8YFLogxK

U2 - 10.1111/1755-5922.12111

DO - 10.1111/1755-5922.12111

M3 - Article

VL - 33

SP - 50

EP - 55

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 2

ER -